Valeant Pharma (VRX) Reports Q3 EPS of $1.15; Narrows Q4, FY12 EPS Outlook
Tweet Send to a Friend
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q3 EPS of $1.15, versus $0.66 reported last year ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
